WO2003063760A3 - Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies - Google Patents

Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies Download PDF

Info

Publication number
WO2003063760A3
WO2003063760A3 PCT/IL2003/000079 IL0300079W WO03063760A3 WO 2003063760 A3 WO2003063760 A3 WO 2003063760A3 IL 0300079 W IL0300079 W IL 0300079W WO 03063760 A3 WO03063760 A3 WO 03063760A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
diagnosing
methods
associated diseases
antibodies directed
Prior art date
Application number
PCT/IL2003/000079
Other languages
English (en)
Other versions
WO2003063760A2 (fr
Inventor
Ehud Gazit
Original Assignee
Univ Tel Aviv Future Tech Dev
Ehud Gazit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/235,852 external-priority patent/US20040052928A1/en
Application filed by Univ Tel Aviv Future Tech Dev, Ehud Gazit filed Critical Univ Tel Aviv Future Tech Dev
Priority to JP2003563456A priority Critical patent/JP2006506942A/ja
Priority to CA2473987A priority patent/CA2473987C/fr
Priority to EP03704977A priority patent/EP1534310A4/fr
Priority to AU2003207973A priority patent/AU2003207973A1/en
Priority to KR10-2004-7011868A priority patent/KR20040081165A/ko
Publication of WO2003063760A2 publication Critical patent/WO2003063760A2/fr
Priority to IL163285A priority patent/IL163285A/en
Priority to AU2004203461A priority patent/AU2004203461B2/en
Priority to US10/901,243 priority patent/US20050020809A1/en
Publication of WO2003063760A3 publication Critical patent/WO2003063760A3/fr
Priority to US11/471,657 priority patent/US7781396B2/en
Priority to US12/458,163 priority patent/US8012929B2/en
Priority to US12/654,461 priority patent/US8697634B2/en
Priority to US13/975,414 priority patent/US8993510B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Abstract

L'invention concerne un peptide comprenant au moins 3 et moins de 15 résidus d'acide aminé, ce peptide contenant une séquence d'acide aminé telle qu'elle parait dans SEQ ID NO:7, ainsi que des compositions pharmaceutiques et des nécessaires le contenant. L'invention concerne également des procédés utilisant ce peptide dans le diagnostic et le traitement de maladies associées à l'amyloïde.
PCT/IL2003/000079 2002-01-31 2003-01-30 Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies WO2003063760A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2003563456A JP2006506942A (ja) 2002-01-31 2003-01-30 アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
CA2473987A CA2473987C (fr) 2002-01-31 2003-01-30 Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies
EP03704977A EP1534310A4 (fr) 2002-01-31 2003-01-30 Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies
AU2003207973A AU2003207973A1 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
KR10-2004-7011868A KR20040081165A (ko) 2002-01-31 2003-01-30 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법
US10/901,243 US20050020809A1 (en) 2002-01-31 2004-07-29 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
AU2004203461A AU2004203461B2 (en) 2002-01-31 2004-07-29 Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
IL163285A IL163285A (en) 2002-01-31 2004-07-29 Peptides, antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US11/471,657 US7781396B2 (en) 2002-01-31 2006-06-21 Peptides directed for diagnosis and treatment of amyloid-associated disease
US12/458,163 US8012929B2 (en) 2002-01-31 2009-07-02 Peptides directed for diagnosis and treatment of amyloid-associated diseases
US12/654,461 US8697634B2 (en) 2002-01-31 2009-12-22 Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US13/975,414 US8993510B2 (en) 2002-01-31 2013-08-26 Peptides and methods using same for diagnosis and treatment of amyloid-associated disease

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35257802P 2002-01-31 2002-01-31
US60/352,578 2002-01-31
US39226602P 2002-07-01 2002-07-01
US60/392,266 2002-07-01
US10/235,852 2002-09-06
US10/235,852 US20040052928A1 (en) 2002-09-06 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US43645302P 2002-12-27 2002-12-27
US60/436,453 2002-12-27

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/235,852 Continuation US20040052928A1 (en) 2002-01-31 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US10/235,852 Continuation-In-Part US20040052928A1 (en) 2002-01-31 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/901,243 Continuation-In-Part US20050020809A1 (en) 2002-01-31 2004-07-29 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Publications (2)

Publication Number Publication Date
WO2003063760A2 WO2003063760A2 (fr) 2003-08-07
WO2003063760A3 true WO2003063760A3 (fr) 2005-02-10

Family

ID=27671045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000079 WO2003063760A2 (fr) 2002-01-31 2003-01-30 Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies

Country Status (6)

Country Link
EP (1) EP1534310A4 (fr)
JP (1) JP2006506942A (fr)
KR (1) KR20040081165A (fr)
AU (1) AU2003207973A1 (fr)
CA (1) CA2473987C (fr)
WO (1) WO2003063760A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927689B2 (en) 2002-12-09 2015-01-06 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US9394628B2 (en) 2004-08-02 2016-07-19 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
CA2530927A1 (fr) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes d'utilisation pour le diagnostic et le traitement de ces maladies
WO2007043048A2 (fr) 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Hydrogels auto-assembles et leurs procedes d'elaboration et d'utilisation
US8101578B2 (en) * 2006-04-28 2012-01-24 Kagoshima University Amyloid [β] Beta fibrillogenesis-inhibiting peptide
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
CA2772488C (fr) 2009-09-11 2018-04-17 Probiodrug Ag Derives heterocycliques en tant qu'inhibiteurs de glutaminyle cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
US9309196B2 (en) * 2010-10-29 2016-04-12 Ramot At Tel-Aviv University Ltd. Indole derivatives and process for their preparation
MX2013005413A (es) 2010-11-15 2014-02-27 Univ Ramot Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides.
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
MX365387B (es) 2012-09-12 2019-05-31 Neurimmune Holding Ag Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
KR101956302B1 (ko) * 2016-11-30 2019-03-11 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
WO2019033099A1 (fr) 2017-08-11 2019-02-14 University Of Kentucky Research Foundation Composé thérapeutique anti-neurodénérescence, procédé de fabrication et utilisation
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344895A (ja) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドａ蛋白質単クロ−ン性抗体
AU7261994A (en) * 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
CA2271291A1 (fr) * 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Proproteines similaires a l'exotoxine de pseudomonas, pouvant etre activees par une protease
JP2000193661A (ja) * 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk 痴呆症の検査方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [online] 18 May 1999 (1999-05-18), XP002999474, Database accession no. (AAW93015) *
DATABASE PROTEIN [online] 31 March 1993 (1993-03-31), XP002999475, Database accession no. (S04016) *
GORMAN ET AL.: "Alzheimer beta-amyloid peptides: Structures of amyloid fibrils and alternate aggregation products", BIOPOLYMERS, vol. 60, no. 5, 2001, pages 381 - 394, XP002999465 *
See also references of EP1534310A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927689B2 (en) 2002-12-09 2015-01-06 Ramot At Tel-Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US9394628B2 (en) 2004-08-02 2016-07-19 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures

Also Published As

Publication number Publication date
WO2003063760A2 (fr) 2003-08-07
KR20040081165A (ko) 2004-09-20
CA2473987C (fr) 2013-11-19
EP1534310A2 (fr) 2005-06-01
EP1534310A4 (fr) 2006-05-31
AU2003207973A1 (en) 2003-09-02
CA2473987A1 (fr) 2003-08-07
JP2006506942A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2003063760A3 (fr) Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies
WO2005000193A3 (fr) Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes d'utilisation pour le diagnostic et le traitement de ces maladies
WO2005018424A3 (fr) Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
WO2007002261A3 (fr) Anticorps bloquant il-1$g(b) et leurs fragments
WO2001005950A3 (fr) Nouveaux procedes permettant la presentation de (poly)peptides/proteines sur des particules bacteriophages au moyen de liaisons disulfure
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
BR0010720A (pt) Peptìdeos de neisseria antigênicos
WO2007029262A3 (fr) Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus
CA2143125A1 (fr) Anticorps specifiques pour une proteine hemostatique, leur utilisation pour l'isolement de la proteine intacte, les compositions hemostatiques depourvues de produits de degradation proeolytique de la proteine
WO1999067382A3 (fr) Sequences d'un facteur de croissance apparente a l'angiopoietine
WO2006028561A3 (fr) Nouveaux polypeptides fabi purifies issus de fransicella tularensis
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
WO2004014937A3 (fr) Peptides dérivés de la thrombine
WO2003022868A3 (fr) Proteines pouvant se lier avec des metaux et procedes associes
CA2319699A1 (fr) Proteine placentaire 13
WO2005116658A3 (fr) Methode de determination d'un processus de degradation tissulaire par detection de neoepitopes comp
EP0816498A3 (fr) Récepteur pour acide aminé excitateur et acides nucléiques liés
WO2003082897A3 (fr) Fragments de peptides actifs synthetiques
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations
WO2004113566A3 (fr) Reseau de proteines associees a une maladie
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
CA2285700A1 (fr) Substance affichant une activite de la renine
AU2003202489A1 (en) Screening method
WO2003070770A3 (fr) Inhibiteur de protease humain de la famille kunitz genetiquement modifie
AU2003222759A1 (en) Method for monitoring collagen type ii degradation in cartilage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2473987

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003704977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1671/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 163285

Country of ref document: IL

Ref document number: 10901243

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003563456

Country of ref document: JP

Ref document number: 1020047011868

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003704977

Country of ref document: EP